3[6]Ulrich,Herrlinger,et al.PrimaryCentralNervous Sytem Lymphomal1991-1197Outcome and Late Asverse Effects Combined Modality Treatment.American Cancer Society,2001,1,(91).
3[1]Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin's lymphoma: a surveillance, epidemiology, and end results analysis [J]. Cancer,2002,95(7):1504-1510.
4[2]Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the ear of highly active antiretroviral therapy [J]. J Neurovirol,2002,Suppl 2:115-121.
5[3]Sparano JA, Anand K, Desai J, et al. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center [J]. J Acquir Immune Defic Syndr,1999,21:S18-S22.
6[4]Cingolani A, Gastaldi R, Fassone L, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas [J]. J Clin Oncol, 2000,18(19):3325-3330.
7[5]Rickert CH, Dockhorn-Dworniczak B, Simon R, et al. Chromosomal imbalances in primary lymphomas of the central nervous system [J]. Am J Pathol,1999,155(5):1445-1451.
8[6]Weller M. Glucocorticoid treatment of primary CNS lymphoma [J]. J Neurol Oncol,1999,43:237-239.
9[7]DeAngelis LM. Primary central nervous system lymphoma [J]. Curr Opin Neurol,1999,12(6):687-691.
10[8]Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary central nervous system lymphoma (PCNSL): the next step [J]. J Clin Oncol,2000,18:3144-3150.
